Early ART-initiation and longer ART duration reduces HIV-1 proviral DNA levels in children from the CHER trial
Authors:
Open Access
- 29 September 2021
- journal article
- research article
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 18 (1) , 1-12
Abstract
Background: Reduction of the reservoir of latent HIV-infected cells might increase the possibility of long-term remission in individuals living with HIV. We investigated factors associated with HIV-1 proviral DNA levels in children receiving different antiretroviral therapy (ART) strategies in the children with HIV early antiretroviral therapy (CHER) trial.Methods: Infants with HIV < 12 weeks old with CD4% ≥ 25% were randomized in the CHER trial to early limited ART for 40 or 96 weeks (ART-40 W, ART-96 W), or deferred ART (ART-Def). For ART-Def infants or following ART interruption in ART-40 W/ART-96 W, ART was started/re-started for clinical progression or CD4% < 25%. In 229 participants, HIV-1 proviral DNA was quantified by PCR from stored peripheral blood mononuclear cells from children who had received ≥ 24 weeks ART and two consecutive undetectable HIV-1 RNA 12–24 weeks apart. HIV-1 proviral DNA was compared between ART-Def and ART-96 W at week 96, and in all arms at week 248. Factors associated with HIV-1 proviral DNA levels were evaluated using linear regression.Findings: Longer duration of ART was significantly associated with lower HIV-1 proviral DNA at both 96 (p = 0.0003) and 248 weeks (p = 0.0011). Higher total CD8 count at ART initiation was associated with lower HIV-1 proviral DNA at both 96 (p = 0.0225) and 248 weeks (p = 0.0398). Week 248 HIV-1 proviral DNA was significantly higher in those with positive HIV-1 serology at week 84 than those with negative serology (p = 0.0042).Intepretation: Longer ART duration is key to HIV-1 proviral DNA reduction. Further understanding is needed of the effects of “immune-attenuation” through early HIV-1 exposure.Funding: Wellcome Trust, National Institutes of Health, Medical Research Council.Keywords
Funding Information
- Wellcome Trust (095182/Z/10/Z)
This publication has 58 references indexed in Scilit:
- Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI StudyPLOS Pathogens, 2013
- Quantification of Unintegrated HIV-1 DNA at the Single Cell Level In VivoPLOS ONE, 2012
- Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwardsAIDS, 2012
- Homeostatic Proliferation Fails to Efficiently Reactivate HIV-1 Latently Infected Central Memory CD4+ T CellsPLOS Pathogens, 2011
- Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradicationAIDS, 2010
- HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferationNature Medicine, 2009
- Expression of Latent HIV Induced by the Potent HDAC Inhibitor Suberoylanilide Hydroxamic AcidAIDS Research and Human Retroviruses, 2009
- Early Antiretroviral Therapy and Mortality among HIV-Infected InfantsNew England Journal of Medicine, 2008
- Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapyProceedings of the National Academy of Sciences, 2008
- Long‐Term Decay of the HIV‐1 Reservoir in HIV‐1–Infected Children Treated with Highly Active Antiretroviral TherapyThe Journal of Infectious Diseases, 2006